Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. - Wikidata - wikimedia - TriplyDB

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

http://www.wikidata.org/entity/Q33562131

about

Diabetes and cancer: two diseases with obesity as a common risk factor Safety of dipeptidyl peptidase 4 inhibitors: a perspective review Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012 Saxagliptin overview: special focus on safety and adverse effects Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Emerging gliptins for type 2 diabetes.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus Incretin-based therapies in prediabetes: Current evidence and future perspectives Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics Incretin therapy--present and future.The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivo Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells Interpreting adverse signals in diabetes drug development programs.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Do GLP-1-based therapies increase cancer risk?Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Sitagliptin: a review.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.A review of gliptins in 2011.Drug-induced pancreatitis.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.

P2860

Q26822753-741028DB-F444-4462-B6C4-86D692F2E8D2 Q26863262-285E07AE-034B-4A3F-82A4-1BF30DA5EA1B Q27007060-C7540685-897C-44DC-A1FF-A17E7C2FFC9F Q28278863-BAD97959-B6D4-4838-9DF9-236E6D1C65BD Q28294225-49961B0B-AFB5-45C1-87F5-A6A4BA09E4EF Q30513617-BC3F2C19-A4BC-4F2F-A171-E79024BE8425 Q33412360-2BEE72EA-7D8F-450D-914F-780CE6B6C087 Q33562235-E6F0E432-B6BD-4621-A595-9E2ACEF7EE83 Q34041974-B1E2568F-B69B-428E-820A-81DA954C97EF Q34128612-B7A3FC02-2092-456F-A3A4-2B8F13537E50 Q34135837-A807EE18-ADDA-4654-95A0-70A32E8113DE Q34347884-E3857E94-AFAC-47BB-A5F9-432AE8CC158B Q34496741-68CF5CB1-634A-45CB-AD0B-753948457C0A Q34699191-E86B0CC1-7DA7-4833-86AB-5E68E81B068E Q35100483-22B20C17-8C46-409F-87E8-0976FD0DF3C8 Q35760283-EAAECF5C-5E26-43A1-8112-DC04E83D7481 Q36064999-94705929-E92B-4349-A05D-5409909C2C2F Q36526318-59D7E84C-68BF-496B-8B4C-50A4AEDDB709 Q36883337-09F85DA5-B275-4E30-9802-5A74F70B8E53 Q36930354-4031C3AE-2E18-4C18-A5C2-F748F041AA03 Q36942266-6079843A-E400-4FBA-9E9D-3965E829E35F Q37193295-424A6C5E-2196-4366-8F4F-3CB925DC9FDD Q37446672-9ED22288-72F2-4E0F-8341-18EBAADD7E99 Q37509313-10B24FDF-12FC-4FBA-BCBF-EFF9D6C45900 Q37577143-E6952007-EB70-4E86-919E-8D5C4E8BE20F Q37779779-D6E3EBEA-CEC6-4175-BB7E-2823A8B30A5D Q37837059-638B2F56-2F89-419B-8436-C393005D305C Q37841554-51D363F1-78DF-4DDB-9ACC-42775226CAED Q37864256-265F511F-5C95-4A80-A5AF-D8306A0FAEF4 Q37866299-65E88C49-F3D8-4407-8B4E-67337C96A7A8 Q37886184-005DFA65-C686-406F-A6D2-AAB6C0CF6CE9 Q37900151-EA58D984-6AB6-49B7-A1A6-B9B7C3618EEF Q37900690-F7BAF182-FF5E-470E-B883-A71193F3EF83 Q37910902-9583415D-29D2-47A2-BBB2-5ABB038ED6B8 Q37929159-D62D04AE-F204-407D-8957-0137BED3D782 Q37964751-07B26BA1-7186-4DF8-A871-BBDEF5B6745E Q37965612-C53CD3C7-CC46-4DEB-84A0-EB6F50772D30 Q37982301-2DDFC712-0FDD-443B-87CE-30CBC9DA53CD Q37995760-FC488A71-04E8-46F9-B755-2B5CA4090D21 Q38004088-30308AFB-83A7-4AB3-9B83-5E83720976C7

P2860

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

http://www.wikidata.org/entity/Q33562131

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@ast

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@en

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@nl

type

label

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@ast

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@en

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@nl

prefLabel

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@ast

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@en

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@nl

P1433

Q33562131-9CE6D10F-5C8E-4408-8DB1-B1C1EC820AAA

P1476

Q33562131-364C6589-EE8E-4095-99E0-C0FBB340C95D

P2093

Q33562131-3F77C531-1015-4E84-81FC-A5291456672C

Q33562131-422FD562-051A-4D62-A3E1-40D905AABAD0

Q33562131-458CDF81-EF5D-4CA0-AB5E-E5E3D3182AC0

Q33562131-76CCC634-9006-4A3B-A950-199B1DE04AE7

Q33562131-7C746F6B-A583-4424-94D2-4E86E3F361AF

Q33562131-860AC45C-5217-4621-9959-86F487924C2B

Q33562131-CC83103E-DA5B-4DFC-806A-13C32349ECA3

P275

Q33562131-D7E5E172-9A99-46D3-9E63-D2D9D87C39D3

P2860

Q33562131-043ABF8E-303C-4AF2-B1F7-48EEF0650285

Q33562131-07D44A89-20ED-4104-81DF-92DE00050C1D

Q33562131-0CEBBAAA-1C6A-4B03-9521-597BB1F857FB

Q33562131-10A7DD75-C48B-4A39-944A-03B4C3FC2BBC

Q33562131-22336F32-22AB-459D-9B6B-EBD125ED963E

Q33562131-273D844F-A4DB-4A12-9C15-9A7E99650C9C

Q33562131-368A2AB1-0A33-4DEB-BB68-556B543B3297

Q33562131-3D78DB76-AA28-4F43-8AC0-98DF2605278F

Q33562131-48FB8511-124F-4C32-875E-F21FE98317FA

Q33562131-4C4D257F-9B21-4A40-B467-A04B6281524A

P304

Q33562131-AECDA7D3-4646-4F47-A6E5-2B9724352A73

P31

Q33562131-A43D1CEF-4DD2-4E05-97CC-CE5CA5754D62

Q33562131-F1A3D4D8-5093-4C89-A72B-A89DAA550FF1

P356

Q33562131-93166BCF-C82E-4774-A141-707D5B3B987B

P433

Q33562131-386DF341-4AF1-4927-83DE-000119BF9370

P478

Q33562131-0CB43005-8985-48AE-8027-11626628C17B

P5008

Q33562131-29E49E9B-E7E2-40C2-8FB9-99172A40C22A

P577

Q33562131-2ABC7A6F-FE24-4578-B9B1-986D7C96964A

Q33562131-EBE341C0-A719-4B51-B0EF-BB5D785F7B64

P5875

Q33562131-CDDC201B-E5BB-4D1D-A8CD-FDAEDF564DB8

P698

Q33562131-FBC560C6-B58B-467D-8547-BC9F6A3F8A21

P921

Q33562131-30EC4817-25D3-4D78-8C42-A40279232FD7

Q33562131-8AEA3212-C4E2-448B-AC93-61B67A3FE13E

Q33562131-A0D7346C-E6FB-4396-8A21-2CACA0DCB0F1

Q33562131-BC86FEB5-26DD-49D9-A1AE-01038664CA11

Q33562131-D3B0B133-8F8C-49A8-B5B2-3BA2BB76E044

P932

Q33562131-26F95550-6E97-45D3-8106-D47D2049BBD4

P356

J.1742-1241.2010.02382.X

P1433

International Journal of Clinical Practice

P1476

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

@en

P2093

B J Goldstein

http://www.w3.org/2001/XMLSchema#string

D E Williams-Herman

http://www.w3.org/2001/XMLSchema#string

G T Golm

http://www.w3.org/2001/XMLSchema#string

K D Kaufman

http://www.w3.org/2001/XMLSchema#string

R J Clay

http://www.w3.org/2001/XMLSchema#string

S S Engel

http://www.w3.org/2001/XMLSchema#string

S V Machotka

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Metformin associated acute pancreatitis.

Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies.

Glucagon-like peptide 1(GLP-1) in biology and pathology.

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.

Metformin induced acute pancreatitis precipitated by renal failure.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

P304

984-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1742-1241.2010.02382.X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2010-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43297993

http://www.w3.org/2001/XMLSchema#string

P698

20412332

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

type-2 diabetes

mechanism of action

maturity-onset diabetes of the young

P932

2904489

http://www.w3.org/2001/XMLSchema#string